Типичный и атипичный оптический неврит

Закрыть метаданные

Рекомендуем статьи по данной теме:

Клинические фенотипы поражения зрительного нерва у пациентов с заболеваниями спектра оптического нейромиелита. Вестник офтальмологии. 2023;(2):61-67

Оптические нейропатии как предмет междисциплинарного изучения. Вестник офтальмологии. 2023;(3):63-70

Сочетание постинфекционного неврита зрительных нервов и синдрома Гийена—Барре. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(9):106-110

Оптический неврит (ОН) является одной из наиболее частых нейроофтальмологических причин потери зрения во всем мире. Демиелинизирующий ОН может быть идиопатическим или являться одним из симптомов аутоиммунных демиелинизирующих заболеваний центральной нервной системы (ЦНС), таких как рассеянный склероз (РС), заболевания спектра оптиконейромиелита (ЗСОНМ), расстройства, ассоциированные с антителами к миелинолигодендроцитарному гликопротеину (МОГАР). Демографические, клинические и рентгенологические признаки ОН при вышеперечисленных заболеваниях ЦНС имеют различия. В связи с этим в настоящее время выделяют типичный и атипичный ОН. Распознавание клинических признаков, отличающих типичный ОН, ассоциированный с РС, от атипичного ОН при ЗСОНМ и МОГАР, имеет важное значение для выбора правильного алгоритма обследования и лечения. В статье обобщены данные клинических, лабораторных, инструментальных методов, применяемых для дифференциальной диагностики ОН.

Ключевые слова:

оптический неврит

MOG-ассоциированное расстройство

заболевания спектра оптиконейромиелита

Авторы:

Шеремет Н.Л.

ФГБНУ «Научно-исследовательский институт глазных болезней имени М.М. Краснова»

ORCID: 0000-0003-4597-4987

Елисеева Д.Д.

ФГБНУ «Научный центр неврологии»

ORCID: 0000-0003-2173-927X

Калашникова А.К.

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России

ORCID: 0000-0002-2229-384X

Захарова М.Н.

ФГБНУ «Научный центр неврологии»

SPIN РИНЦ: 4277-2860
Scopus AuthorID: 7006679636
ResearcherID: C-4611-2012
ORCID: 0000-0002-1072-9968

Дата поступления:

03.08.2023

Дата принятия в печать:

26.10.2023

Список литературы:

Braithwaite T, Subramanian A, Petzold A, Galloway J, Adderley NJ, Mollan SP, Plant GT, Nirantharakumar K, Denniston AK. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurol. 2020;77(12):1514-1523. https://doi.org/10.1001/jamaneurol.2020.3502
Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21(12):1120-1134. https://doi.org/10.1016/S1474-4422(22)00200-9
Zhang YX, Qiu W, Guan HZ, Wu LJ, Ding MP. Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022;13:844155. https://doi.org/10.3389/fneur.2022.844155
De Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol. 2022;269(1):111-124. https://doi.org/10.1007/s00415-020-10352-1
Foo R, Yau C, Singhal S, Tow S, Loo JL, Tan K, Milea D. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022;11(2):184-195. https://doi.org/10.1097/APO.0000000000000513
Gaier ED, Boudreault K, Rizzo JF 3rd, Falardeau J, Cestari DM. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015;15(12):76. https://doi.org/10.1007/s11910-015-0598-1
Sarkar P, Mehtani A, Gandhi HC, Dubey V, Tembhurde PM, Gupta MK. Atypical optic neuritis: An overview. Indian J Ophthalmol. 2021;69(1):27-35. https://doi.org/10.4103/ijo.IJO_451_20
Abel A, McClelland C, Lee MS. Critical review: Typical and atypical optic neuritis. Surv Ophthalmol. 2019;64(6):770-779. https://doi.org/10.1016/j.survophthal.2019.06.001
Margolin E. The swollen optic nerve: an approach to diagnosis and management. Pract Neurol. 2019;19(4):302-309. https://doi.org/10.1136/practneurol-2018-002057
Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines. 2019;7(2):42. https://doi.org/10.3390/biomedicines7020042
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1-16. https://doi.org/10.1007/s00415-013-7169-7
Sharma J, Bhatti MT, Danesh-Meyer HV. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol. 2021;49(2): 186-202. https://doi.org/10.1111/ceo.13863
The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12): 1673-1678. https://doi.org/10.1001/archopht.1991.01080120057025
Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082.e5. https://doi.org/10.1016/j.ophtha.2007.08.004
Bennett JL. Optic Neuritis. Continuum (Minneap Minn). 2019;25(5):1236-1264. https://doi.org/10.1212/CON.0000000000000768
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-169. https://doi.org/10.1016/S1474-4422(11)70274-5
Dobson R, Giovannoni G. Multiple sclerosis — a review. Eur J Neurol. 2019;26(1):27-40. https://doi.org/10.1111/ene.13819
Papp V, Iljicsov A, Rajda C, Magyari M, Koch-Henriksen N, Petersen T, Jakab G, Deme I, Nagy F, Imre P, Lohner Z, Kovács K, Birkás AJ, Köves Á, Rum G, Nagy Z, Kerényi L, Vécsei L, Bencsik K, Jobbágy Z, Diószeghy P, Horváth L, Galántai G, Kasza J, Molnár G, Simó M, Sátori M, Rózsa C, Ács P, Berki T, Lovas G, Komoly S, Illes Z. A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. Eur J Neurol. 2020;27(2):308-317. https://doi.org/10.1111/ene.14079
Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89-100. https://doi.org/10.1016/S1474-4422(22)00187-9
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-2112. https://doi.org/10.1016/S0140-6736(04)17551-X
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477. https://doi.org/10.1084/jem.20050304
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. https://doi.org/10.1212/WNL.0000000000001729
Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85. https://doi.org/10.1038/s41572-020-0214-9
Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Brazilian Committee for Treatment and Research in Multiple Sclerosis. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;41:102045. https://doi.org/10.1016/j.msard.2020.102045
Yamagami A, Wakakura M, Inoue K, Ishikawa H, Takahashi T, Tanaka K. Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan. Neuroophthalmology. 2018;43(2):71-80. https://doi.org/10.1080/01658107.2018.1520905
Симанив Т.О., Кочергин И.А., Захарова М.Н., Коробко Д.С., Заславский Л.Г., Зеленова О.В., Абрамов С.И. Клинико-эпидемиологические аспекты заболеваний спектра оптиконейромиелита в российской популяции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021; 121(7):96-103. https://doi.org/10.17116/jnevro202112107196
Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018;9:888. https://doi.org/10.3389/fneur.2018.00888
Filippatou AG, Mukharesh L, Saidha S, Calabresi PA, Sotirchos ES. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156. https://doi.org/10.3389/fneur.2020.540156
de Sèze J, Arndt C. Neuropathies optiques inflammatoires récidivantes et neuromyélite optique [Recurrent inflammatory optic neuritis and neuromyelitis optica]. Rev Neurol (Paris). 2010;166(12):966-969. https://doi.org/10.1016/j.neurol.2010.09.003
Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013;84(8):922-930. https://doi.org/10.1136/jnnp-2012-302310
Gospe SM 3rd, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond). 2021; 35(3):753-768. https://doi.org/10.1038/s41433-020-01334-8
Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12-16. https://doi.org/10.1001/archophthalmol.2007.26
Nakajima H, Hosokawa T, Sugino M, Kimura F, Sugasawa J, Hanafusa T, Takahashi T. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010;10:45. Published 2010 Jun 18. https://doi.org/10.1186/1471-2377-10-45
Thongmee W, Padungkiatsagul T, Jindahra P, Khongkhatithum C, Thampratankul L, Vanikieti K. Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes. Clin Ophthalmol. 2020;14:4271-4278. https://doi.org/10.2147/OPTH.S285443.
Fukuda TG, Silva ITF, dos Santos TSS, et al. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol. 2022;22:95. https://doi.org/10.1186/s12883-022-02621-5
Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3): 324-330. https://doi.org/10.1001/jamaneurol.2013.5699
Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Continuum (Minneap Minn). 2019;25(3):815-844. https://doi.org/10.1212/CON.0000000000000742
Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K, Saiz A, Lutterotti A, Rostásy K, Höftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017;14(1):208. https://doi.org/10.1186/s12974-017-0984-5
Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children with Demyelinating Syndromes. JAMA Neurol. 2020;77(1):82-93. https://doi.org/10.1001/jamaneurol.2019.2940
Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22(12):1541-1549. https://doi.org/10.1177/1352458515622986
Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022;13:885218. https://doi.org/10.3389/fneur.2022.885218
Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018; 195:8-15. https://doi.org/10.1016/j.ajo.2018.07.020
Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-137. https://doi.org/10.1136/jnnp-2017-316880
Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J. Clinical presentation and prognosis in MOG-antibody disease: a UK study [published correction appears in Brain. 2018;141(4):e31]. Brain. 2017;140(12):3128-3138. https://doi.org/10.1093/brain/awx276
Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46. https://doi.org/10.1186/s12974-015-0256-1
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the NeuromyelitisOptica Study Group (NEMOSMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016; 13(1):280. https://doi.org/10.1186/s12974-016-0718-0
Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, Xu Q, Wei S. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225-231. https://doi.org/10.1016/j.jns.2018.11.029
Zhao G, Chen Q, Huang Y, Li Z, Sun X, Lu P, Yan S, Wang M, Tian G. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33-40. https://doi.org/10.1007/s00415-017-8651-4
Havla J, Pakeerathan T, Schwake C, Bennett JL, Kleiter I, Felipe-Rucián A, Joachim SC, Lotz-Havla AS, Kümpfel T, Krumbholz M, Wendel EM, Reindl M, Thiels C, Lücke T, Hellwig K, Gold R, Rostasy K, Ayzenberg I. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021;18(1):121. https://doi.org/10.1186/s12974-021-02160-9
Levy M, Molazadeh N, Bilodeau PA, Vishnevetsky A, Lotan I, Salky R, Anderson M, Romanow G, Lechner-Scott J, Yeh EA, Giovannoni G. Multiple types of relapses in MOG antibody disease. Mult Scler Relat Disord. 2023;72:104613. https://doi.org/10.1016/j.msard.2023.104613
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111-e120. https://doi.org/10.1212/WNL.0000000000009758
Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, Joldic D, Pittock SJ, Tillema JM, Gorman M, Lassmann H, Lucchinetti CF. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875-892. https://doi.org/10.1007/s00401-020-02132-y
Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu L, Vignal C, Dulau C, Brochet B, Ruet A, Ouallet JC, Gout O, Heran F, Menjot de Champfleur N, Tourdias T, Deneve M, Labauge P, Deschamps R. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017;264(10):2173-2175. https://doi.org/10.1007/s00415-017-8615-8
Cortese R, Battaglini M, Prados F, Bianchi A, Haider L, Jacob A, Palace J, Messina S, Paul F, Wuerfel J, Marignier R, Durand-Dubief F, de Medeiros Rimkus C, Callegaro D, Sato DK, Filippi M, Rocca MA, Cacciaguerra L, Rovira A, Sastre-Garriga J, Arrambide G, Liu Y, Duan Y, Gasperini C, Tortorella C, Ruggieri S, Amato MP, Ulivelli M, Groppa S, Grothe M, Llufriu S, Sepulveda M, Lukas C, Bellenberg B, Schneider R, Sowa P, Celius EG, Proebstel AK, Yaldizli Ö, Müller J, Stankoff B, Bodini B, Carmisciano L, Sormani MP, Barkhof F, De Stefano N, Ciccarelli O; MAGNIMS Study Group. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2023;146(6):2489-2501. https://doi.org/10.1093/brain/awac480
Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuroophthalmology. 2019;44(1):1-4. Published 2019 May 28. https://doi.org/10.1080/01658107.2019.1607883
Ambika S, Durgapriyadarshini S, Padmalakshmi K, Noronha V, Arjundas D. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica. Indian J Ophthalmol. 2022;70(1):194-200. https://doi.org/10.4103/ijo.IJO_887_21
Geng D, Quan C, Li Y. Brain MRI features of Chinese Brain MRI features of Chinese Han patients with MOG-antibody disease. Mult Scler Relat Disord. 2020;43:102167. https://doi.org/10.1016/j.msard.2020.102167.
Saadeh RS, Ramos PA, Algeciras-Schimnich A, Flanagan EP, Pittock SJ, Willrich MA. An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clin Chem. 2022;68(9):1134-1150. https://doi.org/10.1093/clinchem/hvac061
Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl A, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt F, Mader S, Marquard K, Poggenburg I, Pohl D, Pritsch M, Raucherzauner M, Schimmel M, Thiels C, Tibussek D, Vieker S, Zeches C, Berger T, Reindl M, Rostásy K; BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900-908. https://doi.org/10.1212/WNL.0000000000004312.
Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, Kim Y, Park MS, Irani SR, Waters P, Kim HJ. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811-817. https://doi.org/10.1136/jnnp-2017-315998

Закрыть метаданные